In an article published in Psychotherapy and Psychosomatics the effects of antidepressant drugs on well-being in children and adolescents are analyzed.
Recent meta-analyses of the efficacy of second-generation antidepressants for youth have concluded that such drugs possess a statistically significant advantage over placebo in terms of clinician-rated depressive symptoms. However, no meta-analysis has included measures of quality of life, global mental health, self-esteem, or autonomy.
Further, prior meta-analyses have not included self-reports of depressive symptoms. Studies were selected through searching Medline, PsycINFO, and the Cochrane Central Register for Controlled Trials databases as well as GlaxoSmithKline's online trial registry, including self-reports of depressive symptoms and pooled measures of quality of life, global mental health, self-esteem, and autonomous functioning as a proxy for overall well-being.
Result showed a nonsignificant difference between second-generation antidepressants and placebo in terms of self-reported depressive symptoms. Further, pooled across measures of quality of life, global mental health, self-esteem, and autonomy, antidepressants yielded no significant advantage over placebo.
Even though limited by a small number of trials, this analysis suggests that antidepressants offer little to no benefit in improving overall well-being among depressed children and adolescents.